Hikma Pharmaceuticals and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), the world’s fourth largest specialty generic pharmaceutical company, announced today that they have entered into an exclusive licensing and distribution agreement for Ilumya, an innovative biologic product, for the Middle East and North Africa (MENA) region.
CPhI Middle East & Africa has been cancelled due to the COVID-19 pandemic, the 2020 edition of the show, scheduled to take place in September in Abu Dhabi. A new earlier date and location for the event has been disclosed, with the show debuting in Riyadh, Saudi Arabia on March 2021.
CanFite is working on Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the
Nucleix has appointed new CEO, CFO, General Manager and board member, as it opens San Diego office.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020, including revenues
MigVax is getting an investment of $12 million to accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market, as it pioneers the effort to develop Israel’s human vaccine against COVID-19.
The World Health Organisation has issued a guideline to keep safety in schools. We have outlined the most important keys
Hikma has submitted to the US Food and Drug Administration (FDA) its response to deficiencies in its abbreviated new drug application (ANDA) for a generic version of GlaxoSmithKline’s Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).
DURHAM, N.C.–(BUSINESS WIRE)–Nuventra Pharma Sciences is pleased to announce the addition of Iftekhar Mahmood, Ph.D., to its growing team of
Abu Dhabi-based pharmaceutical manufacturer Neopharma and US-based Elevar Therapeutics formed a 50-50 joint venture in UAE, to organize selling Rivoceranib, a targeted anticancer drug and conduct clinical trials for other pipeline candidates.